Should heparin be used to treat thrombocytopenia?;FAUT-IL PRESCRIRE L'HEPARINE POUR FAIRE REMONTER LE CHIFFRE PLAQUETTAIRE?

Sang Thrombose Vaisseaux

Volumn 8, Issue 2, 1996, Pages 125-127

  Caen, Jacques ^a   Bellucci, Sylvia ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PREDNISONE;

BONE MARROW APLASIA; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; SHORT SURVEY; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 0030002066     PISSN: 09997385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (10)

1. Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G. Structure activity relationship in heparin : a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high antifactor Xa activity. Biochem Biophys Res Comm 1983; 116: 492-9.
2. Han ZC, Bellucci S, Shen ZX, et al. Glycosaminoglycans stimulate megakaryocytopoiesis by modifying the activities of hematopoietic growth regulators. J Cell Physiol (soumis à publication).
3. Han ZC, Maurer AM, Bellucci S, et al. Inhibitory effect of platelet factor 4 (PF4) on the growth of Human Erythroleukemia cells. J Lab Clin Med 1992 ; 120: 645-60.
4. Shen ZX, Basara N Xi XD, et al. Fraxiparin, a low-molecular-weight heparin, stimulates megakaryocytopoiesis in vitro and in vivo in mice. Br J Haematol 1994; 88: 608-12.
5. Bellucci S, Han ZC, Caen JP. Studies in vitro of megakaryocytopoiesis in adult immune thrombocytopenic purpura. Eur J Haematol 1991; 47: 86-90.
6. Nichol J, Hornkohl A, Selesi D, Wyres M, Hunt P. TPO levels in plasma of patients with thrombocytopenia or thrombocytosis. 37th annual meeting of the American Society of Hematology. Blood 1995; 86 (suppl.), 1474 (abstract).
7. Shen ZX, Li JM, Wang ZY, Han ZC, Caen JP. Bellucci SA. Thrombocytopoietic effect of heparin given in chronic immune thrombocytopenic purpura, Lancet 1995; 346: 220-1.
8. Or R, Naglet A, Shpilberg O, et al. A randomized double blind placebocontrolled prospective study to evaluate the efficacy and safety of low molecular weight heparin for prevention of veno-occlusive disease or the liver in bone marrow transplantation patients. Transplantation 1996 (sous presse).
9. Amiral J, Meyer D. Rôle du facteur plaquettaire 4 (PF4) dans les thrombopénies induites par l'héparine. Sang Thromb Vaiss 1995; 7: 549-55.
10. Attal M, Huguet F, Rubie H, et al. Prevention of hepatic veno-occlusive disease after bone marrow. Transplantation by continuous infusion or low dose heparin : a prospective, randomized trial Blood 1992; 79: 2834-40.